Advertisement
News
Subscribe to MDT Magazine News

Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.

January 7, 2011 9:34 am | by Bio-Medicine.Org | Comments

VANCOUVER, British Columbia, Jan. 7, 2011 /- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the 4th Annual OneMedForum Emerging Company Finance Conference on Wednesday, January 12 at 8:10 AM PST. The conference is being held at the Sir Francis Drake Hotel in San...

TOPICS:

Sector Snap: Nursing home operators

January 7, 2011 8:46 am | by The Associated Press | Comments

An analyst for Morgan Keegan raised his expectations and price targets for three nursing home operators on Friday, saying a new Medicare reimbursement system will boost their revenue.Analyst Robert Mains said he now expects better results from National HealthCare Corp., Skilled Healthcare Group...

AstraZeneca licenses Amgen drug candidate

January 7, 2011 8:45 am | by The Associated Press | Comments

MedImmune Inc., a unit of AstraZeneca, said Friday it licensed a potential treatment for inflammatory conditions from Amgen Inc.The company licensed AMG-108 for undisclosed financial terms. The deal gives MedImmune rights to develop the drug worldwide, with the exception of Japan.Shares of...

Advertisement

StemCells raises $9.4M by selling 10M shares

January 7, 2011 8:45 am | by The Associated Press | Comments

Stem cell therapy developer StemCells Inc. said Friday it will raise $9.4 million by selling 10 million shares of its stock to institutional investors at $1 per share.The company is selling the shares at a discount of 9.9 percent from its Thursday closing price of $1.11. StemCells said the sale...

Perrigo Company to Present at the 29th Annual J.P. Morgan Healthcare Conference

January 7, 2011 7:32 am | by Bio-Medicine.Org | Comments

ALLEGAN, Mich., Jan. 7, 2011 /- Perrigo Company (Nasdaq: PRGO ; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, at 11:00 AM (PST) at the Westin St. Francis Hotel in San Francisco,...

TOPICS:

Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices Offers Sessions on Orthopedic and Cardio Applications

January 7, 2011 7:32 am | by Bio-Medicine.Org | Comments

LOS ANGELES, Jan. 7, 2011 /- MD+DI ( Medical Device & Diagnostic Industry ), MPMN ( Medical Product Manufacturing News ), and OrthoTec, UBM Canon's Medical Device Media Group leading brands, today announced session topics for the upcoming virtual event, Design Trends: Technological...

TOPICS:

Med device maker Doctors Research lands $7.7M

January 7, 2011 6:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Doctors Research Group Inc. of Southbury, Conn., a maker of a bone cement for repairing cranial defects, has raised $7.7 million of a planned $15 million financing round, according to a regulatory filing.

Hologic pays $125M to acquire Interlace Medical

January 7, 2011 6:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Hologic Inc., a Bedford developer of diagnostics tools for women's health, has acquired Interlace Medical Inc., a Framingham medical device maker, for $125 million.

Advertisement

Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections

January 7, 2011 5:37 am | by Bio-Medicine.Org | Comments

RESEARCH TRIANGLE PARK, N.C., Jan. 7, 2011 /- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of...

TOPICS:

WaferGen to Present at OneMedForum San Francisco 2011

January 7, 2011 5:37 am | by Bio-Medicine.Org | Comments

FREMONT, Calif., Jan. 7, 2011 /- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ), a leading developer of state-of-the-art genomic analysis systems, today announced that it will present an overview of the company at the 4th Annual OneMedForum Business Development and Investment...

TOPICS:

ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics

January 7, 2011 5:36 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Jan. 7, 2011 /- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) today announced that it has signed a term sheet to acquire a private company that holds certain rights and know-how to poloxamer-based therapeutics. The term sheet is non-binding on both ADVENTRX and the target...

TOPICS:

ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million

January 7, 2011 5:36 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Jan. 7, 2011 /- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) announced today that it has entered into definitive agreements to sell 8,184,556 units in a registered direct offering to RA Capital Management, certain healthcare-focused investors, and other institutional...

TOPICS:

Amarin Announces Underwriters' Exercise of Over-Allotment Option

January 7, 2011 5:35 am | by Bio-Medicine.Org | Comments

MYSTIC, Conn. and DUBLIN, Jan. 7, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ) (the "Company"), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, in connection with its previously announced underwritten public offering of American...

TOPICS:

Federal Register: Agency Information Collection Activities; Submission for OMB Review; Comment Request; Medical Devices: Recommended Glossary and Educational Outreach To Suppo...

January 7, 2011 4:31 am | by U.S. Food & Drug Administration | Comments

The guidance document provides guidance for the voluntary use of selected symbols in place of text in labeling. It provides the labeling guidance required for: (1) In vitro diagnostic devices (IVDs), intended for professional use under 21 CFR 809.10...

TOPICS:

Hologic buys Interlace for $125 million

January 7, 2011 3:45 am | by The Associated Press | Comments

Hologic Inc., which makes mammogram systems and other women's health diagnostic tools, said Friday it bought Interlace Medical Inc. for $125 million in cash, in a move to boost its position in the women's health care market.Interlace, based in Framingham, Mass., makes the MyoSure hysteroscopic...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading